

I hereby certify that this paper is being facsimile transmitted to the US PTO central fax number (571-273-8300) on July 31, 2006.


M. Elise Lane

RECEIVED
CENTRAL FAX CENTER
JUL 31 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Attorney Docket No: PNC-001

MERRIL et al.

Group Art Unit: 1649

Serial No: 09/816,289

Examiner: S. Gucker

Filed: March 23, 2001

Title: METHODS FOR TREATING NEURODEGENERATIVE DISEASES
INCLUDING ALZHEIMER'S

SUBSTANCE OF INTERVIEW

Commissioner of Patents
PO Box 1450
Alexandria, Virginia 22313-1450

July 31, 2006

Sir:

A telephonic interview between Dr. Carl Merrill (inventor), the examiner and the undersigned was conducted on June 22, 2006. An Interview Summary from the examiner (mailed June 30, 2006) was received after Applicants filed a Request for Continued Examination.

Generally, claims 1 and 3 – 8 were discussed during the interview, as well as the examiner's position with regard to the outstanding rejection of record. No agreement was reached. Further prosecution is believed necessary to substantiate Applicants' arguments set forth in the response to final rejection.

Respectfully submitted,


M. Elise Lane
Attorney for Applicants
Registration No. 34,409

Panacea Pharmaceuticals, Inc.
207 Perry Parkway, Suite 2
Gaithersburg, Maryland 20877
Tel: (240) 243-8016 (direct)
elisalane@panaceapharma.com